Cargando…

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients

AIM: The purpose of this study is to evaluate and compare the efficacy of 4 prostaglandin analogues (PGAs) and to determine the incidence of ocular surface disease in newly diagnosed, primary open-angle glaucoma (POAG) patients started on one of those 4 PGAs: bimatoprost (benzalkonium chloride, BAK,...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Hajj Moussa, Wissam Georges, Farhat, Rebecca Georges, Nehme, Joseph Claud, Sahyoun, Marwan Antoun, Schakal, Alexandre Raymond, Jalkh, Alexandre Edmond, Abi Karam, Mariana Pierre, Azar, Georges Georges
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863284/ https://www.ncbi.nlm.nih.gov/pubmed/29707390 http://dx.doi.org/10.1155/2018/1319628

Ejemplares similares

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
por: Cai, Ziyan, et al.
Publicado: (2021)

Safety, Efficacy, and Predictive Factors of Conventional Epithelium-Off Corneal Crosslinking in the Treatment of Progressive Keratoconus
por: Farhat, Rebecca, et al.
Publicado: (2020)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
por: Chen, Wensheng, et al.
Publicado: (2014)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
Publicado: (2014)

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases
por: Yamada, Hiroshi, et al.
Publicado: (2016)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study
por: Kammer, J A, et al.
Publicado: (2010)

Tear biomarkers in latanoprost and bimatoprost treated eyes
por: Reddy, Shweta, et al.
Publicado: (2018)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy
por: Kourie, Hampig Raphael, et al.
Publicado: (2015)

Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study)
por: Kim, Joon-Mo, et al.
Publicado: (2021)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi, Matteo, et al.
Publicado: (2014)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
por: Kim, Joon Mo, et al.
Publicado: (2021)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways
por: Li, Xiaohong, et al.
Publicado: (2016)

Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?
por: Dimtsas, Georgios S., et al.
Publicado: (2023)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients
por: Fogagnolo, Paolo, et al.
Publicado: (2015)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda, Yoko, et al.
Publicado: (2016)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma
por: Igarashi, Ryoko, et al.
Publicado: (2014)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi, Hideaki, et al.
Publicado: (2017)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
por: Farris, Edmund P
Publicado: (2008)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

Acute obstructive pyelonephritis due to pelvic organ prolapse: a case-based review of the literature
por: Tayeh, Georges Abi, et al.
Publicado: (2021)

A unified strategy to prostaglandins: chemoenzymatic total synthesis of cloprostenol, bimatoprost, PGF(2α), fluprostenol, and travoprost guided by biocatalytic retrosynthesis
por: Zhu, Kejie, et al.
Publicado: (2021)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Effect of benzalkonium chloride–free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
por: Lopes, Joao F., et al.
Publicado: (2015)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo, Hannu, et al.
Publicado: (2016)

Impact of Latanoprost Antiglaucoma Eyedrops and Their Excipients on Toxicity and Healing Characteristics in the Ex Vivo Eye Irritation Test System
por: Panfil, Claudia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1skq76i6rgvohavb9qg9v649th